Human Prostate Cancer Panel

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10365941" target="_blank" >RIV/00216208:11110/14:10365941 - isvavai.cz</a>

Result on the web

<a href="https://www.biovendor.com/prostate-cancer-panel-human?d=114" target="_blank" >https://www.biovendor.com/prostate-cancer-panel-human?d=114</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Human Prostate Cancer Panel

Original language description

Diagnostic panel for prediction of prostate cancer detection in prostate biopsy. The combination of clusterin and prostate secretory protein-94 increases the accuracy of prostate biopsy indication as compared to the routinely used prostate-specific antigen.

Czech name

—

Czech description

—

Type

Z_tech - Verified technology

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/FR-TI3%2F666" target="_blank" >FR-TI3/666: Identification of novel biomarkers panels in selected malignancies</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Internal product ID

RD11460100CS

Numerical identification

UK1LF14-10559

Technical parameters

The Human Prostate Cancer Assay is a fluorescent bead based immunoassay for the quantitative measurement of human Prostate secretory protein of 94 amino acids (PSP94). This singleplex protein assay is characterized by high sensitivity and wide dynamic range of the measurement. PSP94 is one of the major secretory proteins of the prostate glands. A differential expression between benign tissue and prostate cancer (PC) could make PSP94 a prognostic clinical marker for PC and could help distinguish patients with aggressive forms of PC. A contract for the license of the product has been made between Biovendor (IČ 63471507) and the Charles University (IČ 00216208), No. of Contract UK1LF14-10559, date 30-Sep-2014. The person responsible for dealings is Ing. Michal Karpíšek, Biovendor - Laboratorní medicína a.s., Karásek 1767/1, 621 00, Brno; tel. +420 549 124 186 and MUDr. Otakar Čapoun, Dep. of Urology, First Faculty of Medicine, Charles University, Ke Karlovu 6, 128 08, Praha 2, email: otakar.capoun@lf1.cuni.cz.

Economical parameters

The economic parameters of the multiplex kit from the TIP grant project (FR-TI3/666) refer to the period 2015-2017. The product was just released in 2015 and its further potential increase in sales is linked to the completion of the CE-IVD certification. Diagnostic kit developed under the TIP grant project have an average yearly increase in sales of 35% (2015-2017) and sales strongly vary in time. In addition, the product price is contractual in nature and depends on the number of diagnostic kits purchased in a period of time and the end-user price is not fixed but being always derived from the basic selling price. Basic economic characteristics of the product: basic selling price: 990 EUR / kit; cost (stock): 4900 Kč (190.77 EUR)* ... gain: 799.23 EUR* / kit (80.7%) ... average product revenue growth from the project (2015-2017): 35% ... average revenue share from the project to the company's total revenues: + 0.4% ... share of export to product revenue: 100% (*course on 18/Dec/2017 [1EUR = 25.685CZK]).

Application category by cost

—

Owner IČO

00216208

Owner name

Univerzita Karlova; Biovendor - Laboratorní medicína a.s.

Owner country

CZ - CZECH REPUBLIC

Usage type

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Licence fee requirement

Z - Poskytovatel licence na výsledek nepožaduje v některých případech licenční poplatek

Web page

https://www.biovendor.com/prostate-cancer-panel-human?d=114